Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

NCT01231555 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01231555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01231555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 Administered With Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Terminated
Start date
November 18, 2010
Completion date
July 4, 2011
Enrollment
23 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus